{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:51:45Z","timestamp":1790787105817,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:58:12Z","timestamp":1773161892000},"page":"e715-e721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Zhubin","family":"Gahvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2026.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"[Clinical experiences with sarcolysin in neoplastic diseases]","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann New York Acad Sci"},{"issue":"8354","key":"10.1016\/j.clml.2026.03.005_bib0002","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2026.03.005_bib0003","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V72.6.2015.bloodjournal7262015","article-title":"Prognostic factors with high-dose melphalan for refractory multiple myeloma","volume":"72","author":"Barlogie","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.03.005_bib0004","first-page":"525","article-title":"High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma","volume":"33","author":"Fermand","year":"1991","journal-title":"Nouv Rev Fr Hematol (1978)"},{"issue":"2","key":"10.1016\/j.clml.2026.03.005_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.03.005_bib0006","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.005_bib0007","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.clml.2026.03.005_bib0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2026.03.005_bib0010","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2026.03.005_bib0011","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.005_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.03.005_bib0013","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10192","key":"10.1016\/j.clml.2026.03.005_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.03.005_bib0015","series-title":"Presented at the 6th European Myeloma Network meeting","article-title":"Modeling long-term progression-free survival in transplant eligible and transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, borezomib, lenalidomide and examethasome","author":"Sonneveld","year":"2025"},{"issue":"20","key":"10.1016\/j.clml.2026.03.005_bib0016","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.03.005_bib0017","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0018","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2023000443","article-title":"A rational approach to functional high-risk myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.03.005_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.03.005_bib0020","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International meloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.005_bib0021","series-title":"American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024"},{"issue":"11","key":"10.1016\/j.clml.2026.03.005_bib0022","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.03.005_bib0023","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in Multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.005_bib0024","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.03.005_bib0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jtct.2024.06.030","article-title":"Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian Myeloma Research Group database","volume":"30","author":"Venner","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2026.03.005_bib0026","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1002\/ajh.26530","article-title":"Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.03.005_bib0027","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease -guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"NEJM"},{"issue":"20","key":"10.1016\/j.clml.2026.03.005_bib0028","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.03.005_bib0030","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.03.005_bib0031","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0032","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.clml.2026.03.005_bib0033","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.005_bib0034","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1182\/blood-2024-200210","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)- Master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.03.005_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan","year":"2018","journal-title":"Therap Adv Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.005_bib0036","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41409-018-0261-y","article-title":"Final outcomes of escalated melphalan 280\u2009mg\/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival","volume":"54","author":"Hari","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bmt.2015.211","article-title":"A randomized study of melphalan 200\u2009mg\/m(2) vs 280\u2009mg\/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT","volume":"51","author":"Bensinger","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2026.03.005_bib0038","doi-asserted-by":"crossref","first-page":"486.e1","DOI":"10.1016\/j.jtct.2022.05.022","article-title":"High-dose bendamustine, etoposide, cytarabine, and melphalan (BeEAM) conditioning before autologous transplantation for patients with multiple myeloma","volume":"28","author":"Solomon","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.clml.2026.03.005_bib0039","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.03.005_bib0040","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.clml.2026.03.005_bib0041","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.2025028313","article-title":"High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial","volume":"146","author":"Lahuerta","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2026.03.005_bib0042","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.clml.2026.03.005_bib0043","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.03.005_bib0044","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.bbmt.2019.03.016","volume":"25","author":"Park","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.clml.2026.03.005_bib0045","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1080\/10428194.2020.1811275","article-title":"Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen","volume":"61","author":"Hagen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.03.005_bib0046","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bjh.19281","article-title":"Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma","volume":"204","author":"Hagen","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2022000346","article-title":"Fitness and frailty in myeloma","volume":"2022","author":"Pawlyn","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"23","key":"10.1016\/j.clml.2026.03.005_bib0048","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.03.005_bib0049","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/bjh.19811","article-title":"Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma","volume":"205","author":"Yohay","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.005_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.005_bib0051","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.005_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.02.004","article-title":"Melphalan 140 mg\/m(2) is safe and effective for frail and older multiple myeloma patients with comparable rates of minimal residual disease negativity","author":"Kort","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.clml.2026.03.005_bib0053","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/10428194.2023.2213366","article-title":"Survival outcomes following autologous stem cell transplant with melphalan 140mg\/m(2) versus 200mg\/m(2) preparative regimens in patients with multiple myeloma","volume":"64","author":"Sharma","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.005_bib0054","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/blood-2023-179971","article-title":"Increased exceptional response and overall survival advantage for patients with multiple myeloma receiving Melphalan 200mg\/m 2 vs 140 Mg\/m 2 conditioning for autologous hematopoietic stem cell transplantation","volume":"142","author":"Tjards","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:39:27Z","timestamp":1778067567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000698"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}